Villeneuve J P, Infante-Rivard C, Ampelas M, Pomier-Layrargues G, Huet P M, Marleau D
Hepatology. 1986 Sep-Oct;6(5):928-31. doi: 10.1002/hep.1840060520.
The aminopyrine breath test has been proposed as a quantitative test of hepatic function, but its long-term prognostic value in patients with cirrhosis has not been determined. The aim of this study was to examine the usefulness of the aminopyrine breath test in assessing prognosis and to compare it with traditional methods of evaluating liver function. One-hundred eighty-seven patients with histologically confirmed cirrhosis were studied prospectively. An aminopyrine breath test was obtained at the time of inclusion in the study and results were expressed as per cent of the dose excreted in 2 hr. At inclusion, the severity of liver disease was also assessed according to the Pugh modification of the Child-Turcotte classification based on ascites, neurological status, serum albumin, serum bilirubin and prothrombin time. Mean follow-up was 844 days. During that period, 59 of 187 patients died of their liver disease. Two-year survival decreased with increasing Child-Turcotte classification score: survival was 98% in Child Class A patients (n = 62), 66% in Child Class B (n = 76) and 36% in Child Class C (n = 49) (chi 2 = 65.6, p less than 0.001). Two-year survival also decreased significantly with increasing degree of aminopyrine breath test abnormalities: survival was 90% in patients with aminopyrine breath test greater than 4% (n = 56); 78% in patients with aminopyrine breath test = 2 to 4% (n = 66), and 43% in patients with aminopyrine breath test less than 2% (n = 65) (chi 2 = 36.9, p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
氨基比林呼气试验已被提议作为肝功能的定量检测方法,但它在肝硬化患者中的长期预后价值尚未确定。本研究的目的是检验氨基比林呼气试验在评估预后方面的有用性,并将其与评估肝功能的传统方法进行比较。对187例经组织学确诊为肝硬化的患者进行了前瞻性研究。在纳入研究时进行了氨基比林呼气试验,结果以2小时内排泄剂量的百分比表示。纳入时,还根据基于腹水、神经状态、血清白蛋白、血清胆红素和凝血酶原时间的Child-Turcotte分类的Pugh改良法评估了肝病的严重程度。平均随访844天。在此期间,187例患者中有59例死于肝病。随着Child-Turcotte分类评分的增加,两年生存率下降:Child A级患者(n = 62)的生存率为98%,Child B级患者(n = 76)为66%,Child C级患者(n = 49)为36%(χ2 = 65.6,p < 0.001)。随着氨基比林呼气试验异常程度的增加,两年生存率也显著下降:氨基比林呼气试验大于4%的患者(n = 56)生存率为90%;氨基比林呼气试验为2%至4%的患者(n = 66)为78%,氨基比林呼气试验小于2%的患者(n = 65)为43%(χ2 = 36.9,p < 0.001)。(摘要截断于250字)